Growth in recent years has largely been supported by price increases and new product introductions even as volume growth has been negative or 2-3 per cent at best. Acute therapies, accounting for 62-65 per cent of the IPM, have continued to outpace growth in chronic therapies since FY2022. However, the trend is expected to reverse going forward., Growth in recent years has largely been supported by price increases and new product introductions even as volume growth has been negative or 2-3 per cent at best. Acute therapies, accounting for 62-65 per cent of the IPM, have continued to outpace growth in chronic therapies since FY2022. However, the trend is expected to reverse going forward., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way